基本信息
浏览量:15
职业迁徙
个人简介
Keywords
Therapeutic proteins, DARPins, therapeutic antibodies, adenovirus
Summary & Mission statement
We use protein engineering to develop new protein therapeutics especially for cancer, with an emphasis of solving problems that cannot be addressed by more traditional approaches.We exploit the interdisciplinary nature of our laboratory, bridging protein design, structural biology, protein biochemistry, cell signaling and animal work.
We have developed the ability to rapidly generate highly specific binding molecules to essentially any target, using selection and directed evolution fromsynthetic libraries of Designed Ankyrin Repeat Proteins. The ease of engineering many multispecific formats, tunable half-lives, or chemical derivatization, greatly extends what can be achieved with traditional antibody formats, leading to, e.g., selective induction of apoptosisby several mechanisms as well as other new modes of action. DARPinsare easy to produce, extremely robust and have shown good tolerability in clinical trials. Such projects are carried out from the protein design stage to in vivo efficacy testing.
研究兴趣
论文共 624 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Julia R Ivanova,Amelie S Benk,Jonas V Schaefer,Birgit Dreier, Leon O Hermann,Andreas Plückthun,Dimitris Missirlis,Joachim P Spatz
ACS nanono. 12 (2024): 8919-8933
Human gene therapyno. 5-6 (2024): 163-176
biorxiv(2023)
Scientific Reportsno. 1 (2023): 1-8
crossref(2023)
Cell Death & Diseaseno. 10 (2023): 1-12
Christoph Klenk,Maria Scrivens, Anina Niederer,Shuying Shi, Loretta Mueller, Elaine Gersz,Maurice Zauderer, Ernest S. Smith,Ralf Strohner,Andreas Plückthun
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn